Corteva
CTVA
$13.75
-4.84%
Corteva, Inc. is a pure-play agricultural inputs company, formed in 2019 via the spin-off from DowDuPont, that develops and sells seed products (including the flagship Pioneer brand) and crop protection chemicals such as herbicides, insecticides, and fungicides to farmers globally, with roughly half of revenue generated in North America. As one of the largest global seed and crop protection franchises alongside Bayer, Syngenta, and BASF, Corteva is a scale player in an industry defined by high R&D barriers, long product development cycles, and consolidated competitive dynamics. The dominant investor narrative today centers on the company's planned spin-off of its seeds business into a separate entity named Vylor in late 2026, leaving Corteva as a pure-play crop protection company — a separation intended to unlock differentiated growth and margin profiles for each business. This structural catalyst is colliding with a deeply challenged fundamental picture: a sharp year-over-year revenue decline in the most recent quarter, a swing to losses in late 2025, and a stock price that has collapsed by more than 80% over the past year, raising questions about whether the spin-off can create value amid deteriorating earnings and heavy working capital swings.…
CTVA
Corteva
$13.75
Related headlines
Investment Opinion: Should I buy CTVA Today?
The synthesized recommendation is Hold, with a speculative bias. The core thesis is that the stock is deeply oversold and trades at a forward PE of 2.89x, but the fundamental deterioration and lack of analyst consensus (only one target of $19.00) make it too risky for a Buy. The analyst target implies 59.4% upside, but with only one analyst, this is not a reliable consensus.
Supporting evidence includes the low forward PE of 2.89x based on estimated EPS of $5.16, which suggests the market is pricing in a severe earnings collapse. However, revenue declined 1.19% year-over-year in Q2 2026, and free cash flow is negative, with -$588 million in the most recent quarter. The balance sheet is strong with a debt-to-equity of 0.107 and current ratio of 1.43, but ROE is just 4.53% and the dividend payout ratio of 43.4% may be unsustainable if cash flow does not recover. The stock trades at a PS ratio of 2.62x, well below its historical average, but this reflects the collapse in market cap rather than fundamental improvement.
Key risks include the potential failure of the seeds spin-off to unlock value, continued cash burn, and regulatory headwinds in crop protection. The rating would upgrade to Buy if the company demonstrates revenue stabilization and positive free cash flow for two consecutive quarters, or if the spin-off is completed with favorable terms. It would downgrade to Sell if revenue declines accelerate or if free cash flow remains negative through 2027. The stock appears undervalued relative to its history but may be a value trap given the deteriorating fundamentals.
Sign up to view all
CTVA 12-Month Price Forecast
The stock is deeply oversold and trades at a fraction of its historical multiples, but the fundamental picture remains highly uncertain. The forward PE of 2.89x suggests the market expects a massive earnings recovery, yet recent quarterly losses and negative cash flow make this a high-risk bet. The seeds spin-off is a potential catalyst, but execution risk is high. I would upgrade to bullish if the company reports two consecutive quarters of positive free cash flow and revenue stabilization, and downgrade to bearish if free cash flow remains negative or the spin-off is delayed.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Corteva's 12-month outlook, with a consensus price target around $16.98 and implied upside of +23.5% versus the current price.
Average Target
$16.98
0 analysts
Implied Upside
+23.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$14 - $20
Analyst target range
Analyst coverage of Corteva is extremely thin, with only 1 analyst providing a target price in the provided data, and the consensus recommendation is listed as "none." The single analyst target is $19.00, which implies a +59.4% upside from the current price of $11.92. However, with only one data point, this target lacks statistical significance and should not be interpreted as a reliable consensus. The estimated EPS average of $5.16 (range $5.05 to $5.29) and estimated revenue average of $19.42 billion (range $19.09 billion to $19.80 billion) suggest that the analyst community, while not reflected in the target price count, still expects a substantial earnings recovery.
The institutional ratings data provides a broader view of sentiment, showing a mix of Neutral and Outperform ratings from firms including Argus Research (Buy), Citigroup (Neutral), UBS (Neutral), BMO Capital (Outperform), RBC Capital (Outperform), and JP Morgan (Neutral) as of September 2026. The pattern shows no recent upgrades or downgrades — all actions are reiterations — indicating that analysts are in a holding pattern, likely waiting for clarity on the seeds spin-off and a stabilization in crop protection pricing. The wide gap between the single $19.00 target and the current $11.92 price, combined with the absence of a formal consensus, signals high uncertainty and limited institutional conviction. This lack of coverage depth is consistent with a stock that has experienced a catastrophic decline, as analysts may be reluctant to publish bullish targets amid such severe fundamental deterioration.
Bulls vs Bears: CTVA Investment Factors
The bear case currently has stronger evidence, driven by the stock's 81% one-year decline, negative free cash flow, and deteriorating revenue and earnings. The bull case rests almost entirely on a forward EPS estimate of $5.16 that implies a dramatic recovery, but this is highly uncertain given recent quarterly losses and cash burn. The single most important tension is whether the seeds spin-off in late 2026 will unlock value or whether the company's fundamental deterioration will continue to erode shareholder value. Until there is tangible evidence of revenue stabilization and cash flow recovery, the risk/reward remains skewed to the downside.
Bullish
- Forward PE of 2.89x implies deep value: Based on estimated EPS of $5.16, the forward PE is just 2.89x, a fraction of the trailing PE of 41.89x and well below typical agricultural input peers. This suggests the market is pricing in a severe earnings collapse that may not materialize if the seeds spin-off unlocks value.
- Analyst target implies 59% upside: The single analyst target of $19.00 represents a 59.4% upside from the current price of $11.92. While coverage is thin, this target aligns with the forward EPS estimate and suggests that if earnings normalize, the stock could re-rate significantly.
- Conservative balance sheet with low leverage: Debt-to-equity is only 0.107 and the current ratio is 1.43, indicating minimal financial risk. Interest coverage of 40.7x provides ample cushion to service debt even amid earnings volatility.
- Seeds spin-off could unlock value: The planned spin-off of the seeds business into Vylor in late 2026 could create two focused companies with distinct growth and margin profiles. The seeds segment generated $4.53 billion in Q2 2026 revenue and historically higher margins, potentially attracting a higher multiple as a standalone entity.
Bearish
- Catastrophic price decline with no bottom: The stock has fallen 81.23% over the past year and 86.75% in just the last month, closing at $11.92, merely $0.08 above its 52-week low of $11.84. This relentless selling pressure shows no signs of stabilization and reflects a complete breakdown in investor confidence.
- Revenue and earnings deterioration: Q2 2026 revenue declined 1.19% year-over-year to $6.379 billion, and the company swung to net losses of $552 million in Q4 2025 and $320 million in Q3 2025. Trailing EPS is just $0.024, and the trailing net margin is a razor-thin 6.29%.
- Severe cash flow burn: Free cash flow turned negative at -$588 million in Q2 2026, following a -$2.972 billion outflow in Q1 2026 due to massive working capital drains. TTM free cash flow of $629 million is insufficient to cover the dividend and growth investments, raising sustainability concerns.
- Extreme earnings volatility: Operating margins have swung from -10.3% in Q3 2025 to +30.0% in Q2 2026, highlighting unpredictable profitability. The Q4 2025 loss included a $772 million hit in other expenses, suggesting non-operating charges that could recur.
CTVA Technical Analysis
Corteva is in a severe, sustained downtrend that has wiped out the vast majority of shareholder value. The stock's 1-year price change is -81.23%, with the current price of $11.92 sitting at just 0.1% of its 52-week range (52-week low of $11.84, 52-week high of $90.97) — effectively at the very bottom of its annual range. This positioning is the hallmark of a falling knife rather than a value opportunity, as the stock has shown no ability to establish a durable base and remains within pennies of its 52-week low. The 6-month change of -86.05% confirms the decline is not a recent phenomenon but a persistent, structural breakdown in the equity story.
Short-term momentum is equally catastrophic and shows no sign of stabilization. The 1-month change of -86.75% and 3-month change of -86.11% are nearly identical to the 1-year decline, indicating the selling pressure has been relentless and concentrated in the most recent period rather than a gradual erosion. This is corroborated by the relative strength figures: -87.34% versus the S&P 500 over 1 month and -96.24% over 1 year, meaning Corteva has underperformed the market by an extraordinary margin. The most recent daily move of -5.17% (from $12.57 to $11.92) on elevated volume of 78.6 million shares suggests capitulation-style trading, with no evidence of buyers stepping in to defend the price.
Key technical levels are stark: immediate support sits at the 52-week low of $11.84, just $0.08 below the current price, and a breakdown below that level would signal a continuation of the downtrend into uncharted territory with no historical reference points. Resistance is effectively the entire prior trading range, with the 52-week high of $90.97 representing a 663% gain required just to return to prior highs — an implausible near-term scenario. The max drawdown of -86.83% and the absence of a beta figure in the provided data limit volatility context, but the sheer magnitude of the decline implies extreme idiosyncratic risk; position sizing should assume the stock can continue to gap lower, and the short ratio of 4.31 suggests meaningful short interest that could fuel further downside if negative catalysts persist.
Beta
—
—
Max Drawdown
-86.8%
Largest decline past year
52-Week Range
$9-$15
Price range past year
Annual Return
-78.2%
Cumulative gain past year
| Period | CTVA Return | S&P 500 |
|---|---|---|
| 1m | -84.0% | +1.0% |
| 3m | -84.0% | +2.5% |
| 6m | -83.6% | +13.9% |
| 1y | -78.2% | +15.0% |
| ytd | -79.7% | +13.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CTVA Fundamental Analysis
Corteva's revenue trajectory has turned negative and is deteriorating. The most recent quarter (Q2 2026, ended June 30, 2026) reported revenue of $6.379 billion, a year-over-year decline of 1.19% versus the $6.456 billion reported in Q2 2025. Sequentially, revenue fell from $4.905 billion in Q1 2026 to $6.379 billion in Q2 2026, which is a normal seasonal pattern for agricultural inputs, but the year-over-year contraction is concerning given that Q2 is the peak spring planting season. Segment data shows Seeds generating $4.532 billion and Crop Protection $1.847 billion, meaning the seed business — the segment being spun off as Vylor — remains the dominant revenue driver, and any weakness there disproportionately impacts the whole company. The multi-quarter trend shows Q4 2025 revenue of $3.91 billion and Q3 2025 revenue of $2.618 billion, both below prior-year levels, confirming that the top-line pressure is broad-based rather than a one-quarter anomaly.
Profitability has become highly erratic and is currently under severe pressure. While the most recent Q2 2026 quarter showed net income of $1.161 billion and a gross margin of 54.35%, the trailing twelve-month picture is far weaker: the company swung to a net loss of $552 million in Q4 2025 and a loss of $320 million in Q3 2025, dragging the trailing net margin down to 6.29% and trailing EPS to just $0.024. The gross margin of 47.29% (trailing) is respectable for the agricultural inputs industry, but the operating margin of 15.05% and the volatility between quarters — from -10.3% operating margin in Q3 2025 to +30.0% in Q2 2026 — highlight extreme earnings instability. The Q4 2025 loss was driven in part by a $772 million hit in total other income/expenses, suggesting non-operating or impairment charges that are weighing on reported profitability.
Corteva's balance sheet remains a relative bright spot, but cash flow generation has turned deeply negative. The debt-to-equity ratio is a conservative 0.107, and the current ratio of 1.43 indicates adequate short-term liquidity, while the interest coverage ratio of 40.7x (as of Q2 2026) shows the company can comfortably service its debt. However, free cash flow tells a different story: TTM free cash flow is just $629 million, and the most recent quarter (Q2 2026) saw negative free cash flow of -$588 million, driven by a -$466 million operating cash flow and a $1.42 billion working capital drain. The Q1 2026 quarter was even worse, with -$2.972 billion in free cash flow due to a $4.056 billion working capital outflow, reflecting the seasonal build in receivables and inventory. With ROE at just 4.53% and a dividend payout ratio of 43.4%, the company is returning cash to shareholders while internally generated funds are insufficient to cover both dividends and growth investments, raising questions about the sustainability of the payout if cash flow does not recover.
Quarterly Revenue
$6.4B
2026-06
Revenue YoY Growth
-1.2%
YoY Comparison
Gross Margin
54.4%
Latest Quarter
Free Cash Flow
$629000000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CTVA Overvalued?
Because Corteva's trailing net income is positive but negligible (EPS of $0.024), the trailing PE ratio of 41.89x is effectively meaningless and distorted by a near-zero earnings base. The more informative metric is the forward PE of 2.89x, which is based on estimated EPS of $5.16 — a figure that implies the market expects a massive earnings recovery from current levels. The enormous gap between the trailing PE (41.89x) and forward PE (2.89x) signals that analysts are pricing in a dramatic normalization of profitability, likely tied to the completion of the seeds spin-off and a recovery in crop protection margins. However, given the recent quarterly losses and cash flow deterioration, this forward estimate carries substantial execution risk.
Relative to the broader Basic Materials sector, Corteva's valuation presents a mixed picture. The price-to-sales ratio of 2.62x and price-to-book ratio of 1.89x are not obviously expensive in absolute terms, but the EV/EBITDA of 14.21x is above what is typical for a company with declining revenue and volatile margins. The PEG ratio of 1.89x suggests the stock is trading at a premium to its growth rate, which is difficult to justify when revenue is contracting. Without a sector-average benchmark provided in the data, the most telling comparison is the stock's own history: the current PS ratio of 2.62x is well below the 8.90x seen in Q2 2026 and the 11.57x in Q4 2025, reflecting the collapse in market capitalization rather than a fundamental improvement in the business.
Historically, Corteva's valuation multiples have compressed dramatically as the stock price has fallen. The PE ratio ranged from 8.79x in Q2 2024 to 41.89x currently (trailing), while the PS ratio has fallen from 17.47x in Q3 2024 to 2.62x today. The current PS ratio of 2.62x is near the bottom of its multi-year range, which could suggest a value opportunity if the business stabilizes — but the simultaneous deterioration in revenue, margins, and cash flow indicates this is more likely a value trap than a bargain. The market is clearly pricing in significant fundamental deterioration, and until there is evidence of revenue stabilization and cash flow recovery, the low multiples are unlikely to provide a durable floor.
PE
41.9x
Latest Quarter
vs. Historical
High-End
5-Year PE Range 9x~24x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
14.2x
Enterprise Value Multiple
Investment Risk Disclosure
Corteva faces significant financial and operational risks. The company's revenue declined 1.19% year-over-year in Q2 2026, and it swung to net losses in both Q3 and Q4 2025, with trailing EPS of just $0.024. Free cash flow is deeply negative, with -$588 million in Q2 2026 and -$2.972 billion in Q1 2026 due to working capital drains, while TTM free cash flow of $629 million is insufficient to cover the 43.4% dividend payout. The seeds segment, which generated $4.53 billion in Q2 2026 revenue, is the dominant profit driver and is being spun off, potentially leaving the remaining crop protection business with lower margins and growth prospects.
Market and competitive risks are amplified by the stock's extreme underperformance and valuation uncertainty. The stock has underperformed the S&P 500 by 96.24% over the past year and trades at a forward PE of 2.89x, which could be a value trap if earnings fail to materialize. The agricultural inputs industry is highly competitive, with Bayer, Syngenta, and BASF pressuring pricing and innovation. Regulatory headwinds, such as potential restrictions on crop protection chemicals, could further impair the remaining business after the spin-off. The short ratio of 4.31 indicates meaningful short interest that could exacerbate downside if negative news continues.
In a worst-case scenario, continued revenue declines, cash flow deterioration, and a failed spin-off could drive the stock below its 52-week low of $11.84. If the company fails to achieve the estimated EPS of $5.16 and instead reports another year of losses, the stock could fall to the analyst low target of $19.00 (though this is above current price) or lower, potentially testing single digits. From the current price of $11.92, a drop to $8 would represent a 33% loss, and a decline to the 52-week low of $11.84 is only 0.7% away. The max drawdown of -86.83% illustrates the catastrophic potential if the bear case unfolds.
FAQ
The key risks include financial, operational, and market risks. Financially, free cash flow is negative, with -$588 million in Q2 2026 and -$2.972 billion in Q1 2026, and the dividend payout ratio of 43.4% may be unsustainable. Operationally, revenue declined 1.19% year-over-year in Q2 2026, and the company swung to net losses in Q3 and Q4 2025. The seeds spin-off carries execution risk, and the remaining crop protection business may face lower margins. Market risks include extreme volatility, with a beta not provided but implied by the 86.83% max drawdown, and a short ratio of 4.31 that could amplify downside. Regulatory risks in crop protection could further impair the business.
The 12-month forecast has three scenarios: bull case (20% probability) with a target range of $19-$25, base case (50% probability) with a range of $12-$19, and bear case (30% probability) with a range of $8-$12. The base case is most likely, assuming revenue stabilizes and free cash flow turns positive by mid-2027. The key assumption is that the seeds spin-off is completed on schedule and the company meets its estimated EPS of $5.16. However, if free cash flow remains negative or the spin-off is delayed, the bear case could unfold, pushing the stock below its 52-week low of $11.84.
CTVA appears undervalued on a forward basis but overvalued on trailing metrics. The forward PE of 2.89x is extremely low, suggesting the market is pricing in a severe earnings collapse. However, the trailing PE of 41.89x is distorted by near-zero earnings. The PS ratio of 2.62x is well below its historical average of 8.90x in Q2 2026 and 11.57x in Q4 2025, reflecting the collapse in market capitalization. The EV/EBITDA of 14.21x is above typical levels for a company with declining revenue. The market is pricing in a significant recovery, but if that fails to materialize, the stock could be overvalued even at current levels.
CTVA is not a good buy for most investors due to its extreme volatility and fundamental deterioration. The stock has fallen 81.23% over the past year and trades at $11.92, just above its 52-week low of $11.84. The forward PE of 2.89x suggests deep value, but this relies on an estimated EPS of $5.16 that is far above the trailing EPS of $0.024. The single analyst target of $19.00 implies 59.4% upside, but with only one analyst, this is not a reliable consensus. The biggest downside risk is continued cash burn, with free cash flow at -$588 million in Q2 2026. For risk-tolerant investors, a small speculative position could be justified if they believe in the spin-off catalyst, but for most, it is better to wait for evidence of a turnaround.
CTVA is more suitable for long-term investment by risk-tolerant investors, given the speculative nature of the turnaround and the spin-off catalyst. The stock's extreme volatility, with a 1-year decline of 81.23% and a max drawdown of 86.83%, makes it unsuitable for short-term trading unless one is a momentum trader. The dividend yield of 1.04% is modest and may not be sustainable if cash flow does not recover. Earnings visibility is low, with only one analyst target and no consensus. A minimum holding period of 2-3 years is suggested to allow for the spin-off and potential recovery, but investors should be prepared for further downside.